Canada · Delayed Price · Currency is CAD Green Thumb Industries Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 revenue rose 5% year-over-year to $307 million, with normalized EBITDA of $84 million and strong cash flow. Share repurchases and disciplined CapEx continued, while regulatory progress in Virginia and Texas and potential RYTHM consolidation position the company for future growth.
-
The meeting approved all proposals, including director elections, executive compensation, auditor appointment, and a key amendment to super-voting shares. Strategic updates highlighted regulatory changes, brand growth, and strong financial results, with 2025 revenue at $1.175 billion.
-
Q1 2026 revenue rose 7.5% year-over-year to $300 million, with normalized EBITDA at $93.5 million and record cash of $345 million. Share buybacks and disciplined capital allocation continued, while regulatory changes and new state licenses position the company for future growth.
Fiscal Year 2025
-
Q2 2025 revenue rose 5% to $293M, with adjusted EBITDA of $83M and strong CPG growth, but price compression and regulatory uncertainty pressured margins. The company is investing in THC beverages, expanding market share, and maintaining a strong balance sheet.
-
The meeting covered director elections, executive compensation, auditor appointment, and an amendment to the share plan, with all motions passing by majority vote. No shareholder questions were submitted during the session.
-
Revenue grew 1% year-over-year to $280M, with adjusted EBITDA at $85M and strong cash flow, despite pricing pressures and increased competition. The company maintains a robust balance sheet, focuses on operational efficiency, and expects flat revenue and margin compression in the next quarter.
Fiscal Year 2024
-
Record Q4 revenue and EBITDA were achieved despite ongoing pricing pressure and regulatory uncertainty. Strong cash flow and balance sheet enabled continued investment in growth, innovation, and market expansion, positioning the company to capitalize on rising THC demand and industry shifts.
-
Q3 2024 revenue grew 4% year-over-year to $287 million, with strong CPG and wholesale gains offsetting flat retail sales and ongoing price compression. Strategic debt refinancing improved the balance sheet, while new store openings and brand partnerships expanded market reach.
-
Q2 2024 saw 11% revenue growth to $280M, record cash flow, and margin expansion despite price pressure. Share buybacks, CapEx investments, and new market launches, including Ohio adult-use, position the company for continued growth amid regulatory and economic uncertainty.